Epoetin beta - Roche

Drug Profile

Epoetin beta - Roche

Alternative Names: BM 06019; NeoRecormon; r-HuEPO - Roche; Recormon; RO 205 3859

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Wyeth
  • Developer Roche
  • Class Antianaemics; Colony-stimulating factors; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 02 May 2007 Results from the GAIN study added to the Haematological Disorders therapeutic trials section
  • 19 Jul 2006 Results from a clinical trial (ACORD) in patients with early renal anaemia have been added to the adverse events section
  • 20 Jun 2006 Results from the NAUTICA trial in cancer patients with anaemia have been added to the Haematological Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top